SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Valiant Laboratories Ltd (VALIANTLAB)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543998 NSE: VALIANTLAB Pharmaceuticals & Drugs | Small Cap | Valiant Laboratories Share Price

₹74.70 -1.28 (-1.68%)

As on 04-Jun'26 16:59

Valiant Laboratories Ltd (VALIANTLAB)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543998 NSE: VALIANTLAB Pharmaceuticals & Drugs | Small Cap | Valiant Laboratories Share Price

₹74.70 -1.28 (-1.68%)

As on 04-Jun'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹406 Cr.
Current Price
₹74.7
52-Week Low / High
₹50 / 115
TTM EPS
₹1
TTM Sales
₹217 Cr.
Book Value per Share
₹58.9
P/E Ratio
73.14
Industry PE
46.5
Price to Book (P/B)
1.27
Lower than its 5-year historical median
Price to Sales (P/S)
1.87
Lower than its 5-year historical median
EV/EBITDA
39.63
Higher than its 5-year historical median
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
-0.91%
Underperforms industry median
Return on Capital Employed (ROCE)
-0.43%
Underperforms industry median
Return on Assets (ROA)
-0.67%
Operating Profit Margin
-1.1%
Net Profit Margin
-1.61%
Gross Profit Margin
0.4%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-26.75%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-732.35%
Asset Quality
Promoter Holding
74.94%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹265 Cr.
Equity
₹54.3 Cr.
Face Value
₹10
All Time Low / High
₹50.00 / 210.64

Valiant Laboratories stock performance

Key Ratios
mw4me loader

Check Before You Invest

Valuation

Somewhat Undervalued

Price Trend

Strong
Q.1 Is Valiant Laboratories Ltd a good quality company?
Valiant Laboratories Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Valiant Laboratories Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Valiant Laboratories Ltd vs industry peers?
Valiant Laboratories Ltd revenue CAGR is -22.95%, compared to the industry median CAGR of 6.81%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of Valiant Laboratories Ltd?
Promoters hold 74.94% of the Valiant Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Valiant Laboratories Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of -19.75% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Valiant Laboratories Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 31.6%26.3%-0.3%-0.4%-
Value Creation
Index
1.30.9-1.0-1.0-

Growth Parameters

Sales 292334182133217
Sales YoY Gr.-14.5%-45.5%-26.8%-
Adj EPS 7.68.2-0.5-0.31
YoY Gr.-6.7%-105.5%NA-
BVPS (₹) 20.428.750.650.158.9
Adj Net
Profit
26.828.6-2.1-1.26
Cash Flow from Ops. 2.32348.8-21.9-
Debt/CF from Ops. 272.61.2-2.7-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales NANA-23%-26.8%
Adj EPS NANA-132%NA
BVPSNANA35%-1.1%
Share Price - - - -24.8%

Key Financial Parameters

Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
37.533.3-1.3-0.51.9
Op. Profit
Mgn %
14.510.5-4.6-1.13.3
Net Profit
Mgn %
9.28.6-1.2-0.92.6
Debt to
Equity
0.90.60.30.30
Working Cap
Days
0156226236139
Cash Conv.
Cycle
06889120104

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25
Sales292334182133
Operating Expenses + 249299190138
Manufacturing Costs8131410
Material Costs234277168116
Employee Cost 3544
Other Costs 4548
Operating Profit 4235-8-5
Operating Profit Margin (%) 14.5%10.5%-4.6%-3.5%
Other Income + 25105
Exceptional Items 0000
Interest 0000
Depreciation 2222
Profit Before Tax 4238-1-1
Tax 149-11
Profit After Tax 27290-2
PAT Margin (%) 9.4%8.7%0.2%-1.6%
Adjusted EPS (₹)7.88.30.1-0.5
Dividend Payout Ratio (%)0%0%0%0%

Valuation of Valiant Laboratories - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 71100237234
Share Capital 16334343
Reserves 5568193191
Debt +61595959
Long Term Debt59595959
Short Term Debt1000
Minority Interest0000
Trade Payables46472519
Others Liabilities 3644
Total Liabilities 182213325317

Fixed Assets

Net Fixed Assets +22303230
Gross Block30394243
Accumulated Depreciation891113
CWIP 1000
Investments 034119165
Inventories1613104
Trade Receivables111894672
Cash Equivalents 2009727
Others Assets 11472219
Total Assets 182213325317

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 22349-22
PBT 4238-1-1
Adjustment 3224
Changes in Working Capital -28-847-28
Tax Paid -14-913
Cash Flow From Investing Activity + -12-21-18325
Capex -7-7-4-1
Net Investments -0-34-85-46
Others -520-9472
Cash Flow From Financing Activity + 6-2136-1
Net Proceeds from Shares 4901360
Net Proceeds from Borrowing 0000
Interest Paid -1-0-0-0
Dividend Paid 0000
Others -42-1-0-0
Net Cash Flow -4023

Financial Ratio

PARTICULARSMar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)38.4833.730.2-0.91
ROCE (%)31.6226.29-0.3-0.43
Asset Turnover Ratio1.61.690.680.42
PAT to CFO Conversion(x)0.070.79N/AN/A
Working Capital Days
Receivable Days138.70109134.60161.20
Inventory Days19.8015.8023.1019.10
Payable Days72.4061.9078.5069.50

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Valiant Laboratories Ltd FAQs

The current trading price of Valiant Laboratories on 04-Jun-2026 16:59 is ₹74.70.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Valiant Laboratories stood at ₹405.7 Cr

The latest P/E ratio of Valiant Laboratories as of 03-Jun-2026 is 73.14.

The latest P/B ratio of Valiant Laboratories as of 03-Jun-2026 is 1.27.

The 52-week high of Valiant Laboratories is ₹114.7 and the 52-week low is ₹50.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Valiant Laboratories is ₹217 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Valiant Laboratories Ltd is a below average quality company.

The key valuation ratios of Valiant Laboratories Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Valiant Laboratories Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Valiant Laboratories Ltd

Valiant Laboratories was originally formed as a partnership firm under the name and style of ‘M/s. Bharat Chemicals’ pursuant to the deed of partnership dated October 17, 1980, amended and restated from time to time. Subsequently, the partnership firm, M/s. Bharat Chemicals was converted into a public limited company under the provisions of the Companies Act with the name “Valiant Laboratories Limited” pursuant to certificate of incorporation dated August 16, 2021 issued by the by Central Registration Centre, Registrar of Companies. 

The company is an Active Pharmaceutical Ingredient (API) / Bulk Drug manufacturing company having focus on manufacturing of Paracetamol. Bulk drugs/Active Pharmaceutical Ingredients (API) serve as raw materials for manufacturing finished dosage forms or formulations. Paracetamol (Scientific name: Acetaminophen or para-hydroxyacetanilide - C8H9NO2), is one of the most commonly taken analgesic worldwide and is recommended as the first-line therapy in pain conditions by the World Health Organization (WHO). Paracetamol has several applications such as usage in treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold and fever. The company manufacture Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers. Paracetamol was initially approved by the U.S. Food and Drug Administration (USFDA) in 1951 and is available in a variety of forms including syrup form, regular tablets, effervescent tablets, injection, suppository, and other forms. Paracetamol is often found combined with other drugs in many over the counter (OTC) allergy medications, cold medications, sleep medications, pain relievers, and other products.

The company was originally formed in year 1980 as a partnership firm under the Indian Partnership Act, 1932 under the name and style of ‘Bharat Chemicals’ and gradually, commenced manufacturing of Paracetamol by late 1982. In August 2021, its partnership firm was converted into a public limited company registered under the Companies Act. Its manufacturing facility is located at Plot nos. L-13 and L-30, Tarapur Industrial Area, Boisar, Palghar, in the state of Maharashtra, India. The company’s Manufacturing Facility employs modern machinery and equipment to ensure smooth flow of operations. It is holding certificate of good manufacturing practices (GMP) for manufacture and sale of bulk drugs / API and ISO 9001:2015 certification. Its quality control team monitors the manufacturing process at all stages from initial testing stage for incoming raw material to the final product prior to packing. 

Business area of the company

Valiant Laboratories is a leading Active Pharmaceutical ingredient manufacturing company with its focus on manufacturing Paracetamol API/Bulk Drug which has several applications like uses in treatment of conditions such as headache, muscle ache, arthritis, back ache, toothache, cold and fever. 

Product of the company

  • Paracetamol/Acetaminophen

Key events and milestones

  • 1980: Formed Bharat Chemicals (a partnership firm).
  • 1981: Acquired plot No. L-30 in the Tarapur Industrial Area, Palghar, Maharashtra on leasehold basis admeasuring about 1,000 sq. mtrs.
  • 1982: Commenced manufacture of Paracetamol.
  • 2004-05: Acquired additional Plot Nos. L-28, L-28 (part), L-29 and L-13 at Tarapur Industrial Area, Palghar, Maharashtra collectively admeasuring about 3,000 sq. mtrs.
  • 2015: Annual revenue from operations crossed Rs 500 million.
  • 2021: Converted from partnership firm into a public limited company.
  • 2021: Annual revenue from operations crossed Rs 1,000 million.
  • 2022: Annual revenue from operations crossed Rs 2,000 million.
  • 2022: Formed wholly owned subsidiary, VASPL to diversify business activities.
  • 2023: The company got listed on BSE and NSE on October 6, 2023.
  • 2025: Enhanced the manufacturing capacity of the Tarapur plant from 750 MT to 900 MT per month.

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×